August 19, 2026

expert reaction to the TV show ‘The Great ADHD Myth?

Scientists comment on the Channel 4 TV show ‘The Great ADHD Myth?’ 

Prof Katya Rubia, Professor of Cognitive Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, said:

“My own contribution to this programme has been largely misrepresented as my comments were cherry-picked, truncated and presented out of context to make them fit into the programme’s narrative that ADHD does not exist and there is no brain basis to the social construct.

The claim that ADHD is not a disorder of the brain

“It is true that with current technology (which might well change in the future) we cannot diagnose ADHD children based on a brain scan and the diagnosis is based on behavioural questionnaires and observations that are subjective. However, this does not mean that there are no neurobiological correlates to ADHD. There are differences in genetic, neurochemical, even immunological features and there is consistent evidence from three decades of neuroimaging research including my own for differences in brain structure and function as well as connectivity between children with and without ADHD. It is true that they are small at a group level, and that some children have no brain differences based on normative modelling studies. However, part of the reason the differences between ADHD and non-ADHD brains are small at group level is because there is a large heterogeneity, with some children showing large brain differences and other milder cases showing very small differences, so this will bring the average down. There is also substantial evidence for a delay in normal brain maturation in children with ADHD. Crucially, we need to take into account that the youngest and most severe cases with ADHD have never been scanned and if someone behaves very differently from the norm their brain will also function differently.

The “Experiment”

“This “experiment” provided nothing but anecdotical evidence confounded by a host of factors. The child was not only taken off medication, but also off screens, off additives and junk food, subjected to more nature experience and by implication to more interaction with family, friends and parents. This can lead to greater happiness and stronger family bonds (for every child, not just ADHD children). There was the uncontrolled placebo effect of being treated on TV. Published research on interviews with children on their experience with medication shows the exact opposite: most children report that they prefer to be on medication precisely because they have better control over their emotions and consequently more friends and better relationships with others. Substantial research on the effects of nutrition, supplements, exercise, neurofeedback, cognitive training and nature exposure shows unfortunately mostly non-significant or very tiny effects in children with ADHD, very inferior to the effects of medications.

The negative portrayal of stimulant medication as drugging and zombifying children with ADHD

”Substantial evidence from epidemiological studies shows that long-term use of medication in ADHD is associated with many benefits such as reduced rates of suicide, comorbidities, crime, traffic accidents, and substance abuse. The side effects are relatively minor and benefits are very large compared to other drugs in psychiatry. Brain imaging studies over 3 decades have not shown any detrimental effects on brain development. No mention was made about the potential negative consequences of Mason’s dropping school performance on his self-esteem and academic future. Left untreated, ADHD is associated with many negative outcomes such as academic failure, unemployment, emotional instability, secondary depression, substance abuse, etc.

Where does the popular misunderstanding of ADHD come from?

“In my view ADHD is so misunderstood and misportrayed in the media because the traits of ADHD are normally distributed in the population, with ADHD being the extreme end of a continuum. This is different from other psychiatric disorders, for example schizophrenia, where we have a more categorical cut-off of either hallucinating or not. Anyone who has ever seen a severe case of a child with ADHD will not doubt that ADHD exists. However, milder cases can be perceived as more lively or funny children. Many children with impulsiveness or inattention can function well in life and they will not be diagnosed with ADHD unless the problems are perceived as impairing their daily life. The program made it look like everyone with mild features of inattention or impulsiveness will immediately be diagnosed with ADHD and put on ADHD medications whether they need it or like it or not.

Why are programmes like this one irresponsible?

“Biased programs like this one that push their view of ADHD as a mythical entity are irresponsible and will have detrimental effects, in particular at a time in our society where mental health conditions are escalating and where there is an urgent need for early diagnosis and early treatment to prevent further damage down the line. In the UK, ADHD is largely underdiagnosed and undermedicated. Parents of children with ADHD may take their children off medication as seen on the program, which could potentially lead to an increase of the risk of longer-term adverse outcomes of untreated ADHD such as increased anxiety and depression, lower self-esteem, greater risk of substance abuse, suicide, more antisocial behaviour and poorer academic achievement (as already observed by the teachers of Mason), more school-drop-outs, more accidental injuries, worse social functioning and reduced employment prospects later in life.”

Prof Anita Thapar, Honorary Professor and Clinician Scientist at Cardiff University’s School of Medicine, said:

“NICE guidance on ADHD treatment recommends: starting with non-pharmacological interventions first e.g. lifestyle (including diet, sleep, exercise, nature/fresh air, digital care) and environmental adjustments. Evidence on impact of supplements on ADHD is absent. Medication is second line intervention when first line not enough. There is not good evidence factors such as screen time and ultra processed food cause ADHD but as for so many health conditions -lifestyle is important as a component of intervention.

“The evidence base for safety and efficacy of medication is huge and applies to those who meet carefully and thoroughly assessed people who meet diagnostic criteria for ADHD. Any medication involves weighing up risks vs benefits and talking to the patient about these and their own perspectives.

“For those who need it, ADHD medication has a big effect size -larger than for many blood pressure and lipid lowering medications.

“Unsupported ADHD has been shown to be associated with multiple risks and adverse outcomes including suicide, accidents, involvement in the criminal justice system and premature mortality. Medication is associated with reductions in many of these risks as well as in randomised controlled trials (gold standard in the NHS) impacting on ADHD symptoms and quality of life.

“ADHD is hugely variable-just like other conditions in the NHS (e.g. diabetes, high blood pressure); every individual with a diagnosis is not identical.  Some people will not need medication and will manage with lifestyle and environmental changes, others will need medication only when needed e.g. school or work days, others only in the short term and others in the long term.

“Brain imaging is a young science and currently cannot be used to diagnose ADHD and many other conditions including schizophrenia, epilepsy, migraine. So it’s not helpful a clinical statement to say it’s ‘not a disorder of the brain’.

“It’s not a helpful argument to say ADHD is a ‘social construct -the definition which we use (for clinical purposes) is to inform us about the well documented risks and adverse outcomes of people who meet this definition and how to help them (as per NICE guidance).

“I would recommend anyone considering coming of ADHD medication that this is done under clinical supervision with appreciation of the risks vs benefits for that individual (everyone with ADHD is not the same). It’s often done for children-trial to see if they can manage e.g. in summer holidays.

“One can’t tell what the quality of the video assessment the presenter undertook was . The programme focused on symptoms but for a diagnosis, impairment of functioning and severity across settings is needed. It takes time to conduct a proper and thorough assessment including information from informants (ie not just the person themselves)

Assessment needs to be high quality and quality control of services prioritised by govt (see NHS England Independent ADHD Taskforce report)

“We don’t know about the validity of diagnoses from private clinics -presumably variable -some good quality, others less so would imagine. Regulation is important whether NHS or private.

“The programme did not use experts in clinical research on ADHD or consider all the risks of ADHD that have been shown. It seemed one sided and used sensational language e.g. likening medication to corporal punishment.”

Prof Subodh Dave, President of the Royal College of Psychiatrists, said:

“The way we speak about neurodevelopmental conditions really matters. It can fuel harmful stigma experienced by people living with the condition and risk discouraging people from seeking the support and treatment they need.

“While we understand individuals may have their own opinions about the diagnosis and treatment of ADHD, the College takes an evidence-based approach. Research suggests 3 to 5% of the population have ADHD, indicating that it is still under-recognised, under-diagnosed and under-treated in the UK.

“The sharp increase in ADHD waiting lists and diagnoses in recent years needs to be better understood. It might be explained by improvements in public awareness of these conditions, misdiagnosis due to poor quality assessments and a variety of other factors, but invalidating the condition does a disservice to people with ADHD and professionals involved in their care.

“Early years support and reasonable adjustments at school and work can help reduce the impact that ADHD has on people’s lives. The Independent ADHD Taskforce report made it clear that systemic changes across health, education and employment are needed to better meet the needs of people with ADHD and their families and carers. We support a wider societal and public health approach alongside action to improve access to high-quality care for people with ADHD.

“What should be scrutinised is the quality of assessment patients are receiving and whether people are able to access the right support at the right time. Many social, cultural and health factors can influence someone’s likelihood of being diagnosed with ADHD, and these complexities are not always captured in a 45-minute assessment.

“An ADHD diagnosis should never be based solely on questionnaires. It requires a comprehensive clinical assessment that considers differential diagnoses, co-occurring conditions and an individual’s wider circumstances. Getting this right is essential, as both missing or misdiagnosing ADHD and related conditions can have lasting consequences for patients.

“People who have ADHD should be provided with a personalised treatment plan which may include a range of different options, including lifestyle changes, organisational skills training, an ADHD coach, therapy or medication. It is vital they receive the combination of support that works best for them and that this is tailored to their individual needs.

“The focus should be on improving access to high-quality assessments and care by addressing waiting lists that leave many people without vital support for years at a time, not questioning the legitimacy of a well-established neurodevelopmental disorder. A needs-based approach would also help ensure people who are waiting for an assessment and may have a co-occurring mental illness or neurodevelopmental condition can still receive other forms of care and support.

“We would advise anyone who wants to stop taking their ADHD medication to speak with their doctor first.”

Dr Jessica Eccles, Reader (Associate Professor) in Brain-Body Medicine, Brighton and Sussex Medical School, said:

What can the Mason ‘experiment’ actually tell us?

“Nothing that would count as evidence in any scientific sense, and the programme’s own footage inadvertently demonstrates why. What is presented as an experiment is a single, unblinded, uncontrolled case study, filmed for television, in which a family who had already decided to try coming off medication were coached through six simultaneous lifestyle changes at once: medication withdrawal, removal of all screens and gaming devices, a new diet (no ultra-processed food, no sugary sweets, increased protein), unnamed nutritional supplements, a yoga routine, and substantially more one-to-one outdoor time and parental attention.

“With six variables changing together, there is no way to attribute anything that follows to any one of them, let alone to establish that ADHD itself is not real. This is Mill’s basic requirement for causal inference — change one thing at a time — and the film violates it comprehensively. On top of that:

•     N = 1. A single child’s response, however filmed and narrated, cannot generalise to a condition affecting an estimated 3–5% of the population; it isn’t a study, it’s an anecdote.

•     No control condition and no blinding. Everyone involved — Mason, his mother, his teacher, the presenter — knew medication had been stopped and knew cameras were rolling, which is a well-documented recipe for expectancy and observer effects (the Hawthorne effect) in both directions.

•     A large, simultaneous increase in positive attention. The family spent “more time… together as a family,” with a coach, a nutritionist and a film crew newly present in the house. It would be surprising if a child’s mood and behaviour did not improve for a period given that much additional structured attention, irrespective of medication status.

•     The follow-up period was too short, and the programme’s own data undercuts its conclusion. By week five, the child’s teacher was recording him as “more disruptive, more talkative, more fidgety, disengaged,” struggling to complete work he had previously managed, and his mother described him needing “normal breaks” and getting frustrated that he “can’t do it” anymore. That is the clinical picture the medication had been controlling, re-emerging on cue — which is closer to evidence for the diagnosis than against it.

“A responsible interpretation is that this sequence shows what child ADHD services already know: structure, routine, exercise, nature and reduced screen use are good for most children’s regulation and mood, medication changes are naturally followed by a return of pre-treatment symptoms once drug levels fall, and a single family’s six-week experience, filmed for entertainment, cannot answer a scientific question about whether a condition with a 70–80% heritability and a 200-year documented history is “real.” Using it as the narrative spine of a documentary that concludes ADHD is a myth is a serious misuse of what is, at best, a human-interest vignette.

Is there evidence that ultra-processed food, sugar, screens or time in nature cause ADHD (or its symptoms)?

1.  Diet and sugar

“There is a growing evidence base linking higher intake of ultra-processed food with more ADHD symptoms in cross-sectional and cohort studies, and some data associating sugar intake with hyperactivity ratings. This is worth taking seriously as one of several modifiable factors that can affect how symptomatic a child appears. But nearly all of this literature is observational and correlational, and the studies themselves are careful to flag the obvious confounds the documentary ignores: children with more impulsive, reward-driven eating patterns (a recognised feature of ADHD itself) tend to select more processed, sugary food, so the causal arrow plausibly runs partly from ADHD traits to diet, not only the other way round; family income, parental mental health, sleep and general chaos in the home independently predict both diet quality and behavioural symptoms; and no randomised controlled trial has shown that removing ultra-processed food or sugar from an already-diagnosed child’s diet resolves ADHD. NICE’s own guideline does not list dietary elimination as a treatment for ADHD; it recommends a healthy, balanced diet for all children as general good practice, and suggests a formal dietary assessment only where a clear food–symptom link is reported by the family, with any exclusion diet supervised by a dietitian — a world away from the blanket claim made in the film that sugar and processed food are “implicated” in causing the disorder.

2)     Screens

“The claim that any child “100% guaranteed” would look ADHD-like after screen use is not supported by the research. Large longitudinal studies and a 2022 Mendelian randomisation analysis — a design specifically built to test causality rather than mere association — have found no good evidence that early screen exposure causally produces later inattention or hyperactivity symptoms; where correlations exist, more recent work using genetically informed and cross-lagged designs points toward children with higher pre-existing ADHD traits being drawn to screens (again, reverse causation), rather than screens creating the traits. Excess recreational screen time has plenty of other reasons to be limited in children — sleep, physical activity, mood — but the causal claim made in the documentary outstrips what the data will support.  ADHD existed before screens.

3)     Nature, exercise and structure

“Short exposure to green space and physical activity does measurably improve attention and mood in the general population, including in children with ADHD — this is well replicated. But an effect that improves attention in everyone is a marker of general wellbeing benefit, not evidence that the underlying condition doesn’t exist; the same is true of exercise for depression, which helps substantially without meaning depression isn’t real. NICE recommends exercise, sleep hygiene and structured routines as sensible adjuncts alongside — not instead of — evidence-based treatment for ADHD, precisely because they help general functioning without being disease-modifying.

What is the evidence base for ADHD medication — efficacy, safety and side effects such as reduced energy or feeling ‘less fun’?

“ADHD medications (stimulants such as methylphenidate and lisdexamfetamine, and non-stimulants such as atomoxetine and guanfacine) are among the most extensively studied classes of drugs in psychiatry. Cochrane reviews and large meta-analyses — spanning well over 100 randomised, placebo-controlled trials and tens of thousands of participants — consistently show moderate-to-large effect sizes for reducing core inattentive, hyperactive and impulsive symptoms, comparing favourably with effect sizes for many accepted treatments in general medicine. Beyond symptom scores, register and cohort studies (not just short trials) link treatment with real-world functional outcomes: better academic attainment, fewer unintentional injuries and road traffic accidents, lower rates of substance misuse and criminal offending, and — importantly given how the film frames medication as purely cosmetic — a reduction in suicide attempts, an outcome that matters given adults with untreated ADHD carry a substantially elevated risk of self-harm.

“None of this means medication is free of downsides, and the film is right that side effects are real and should be discussed honestly: reduced appetite, sleep disruption, increased heart rate and blood pressure (requiring monitoring), and in children, a modest, usually reversible slowing of growth that is why height and weight are tracked at every review. The subjective experience some patients and families describe — feeling flatter, “less fun,” less spontaneous — is a recognised phenomenon, sometimes linked to dose being higher than needed, and is exactly the kind of individual response that a proper titration and review process (which NICE mandates) is designed to catch and adjust for. It is a legitimate conversation to have with a prescriber about dose and choice of medication; it is not evidence that the underlying difficulty being treated is fictional, any more than a patient feeling drowsy on an antihistamine means their hay fever isn’t real. Every effective medicine trades a benefit against some cost, and ADHD medication is monitored, titrated and reviewed — including at least annually, with an explicit discussion of whether to continue — specifically because that trade-off is taken seriously in UK practice.

Brain imaging, ‘no biological marker’ and the claim ADHD ‘doesn’t exist in the material reality of the brain and body’

“The documentary conflates two different claims that need separating: (a) no brain scan can currently diagnose ADHD in an individual, which is true; and (b) therefore there is no biological basis to ADHD and it doesn’t exist in the brain or body, which does not follow and is contradicted by a large body of evidence.

On (a): this is true of the overwhelming majority of psychiatric diagnoses, and of a great many physical ones — migraine, irritable bowel syndrome, fibromyalgia, most epilepsy, functional cardiac symptoms and chronic pain conditions are all diagnosed clinically, without a scan or blood test that can pick out one individual’s brain or body as abnormal. Group-level statistics not translating into an individual diagnostic test is a limitation of current imaging resolution and inter-individual variability, not proof of non-existence — and it is worth noting explicitly that this is exactly what Professor Rubia herself says in the interview (“based on group statistics… there are differences”), immediately before the film’s narration reframes that as evidence there is nothing there at all.

On (b): at group level, the evidence for a neurobiological basis is substantial and long-standing. The ENIGMA-ADHD mega-analysis (Hoogman et al., Lancet Psychiatry, 2017), pooling MRI data from over 3,200 participants across dozens of international sites, found significantly smaller volumes in several subcortical brain regions (including the amygdala, caudate, putamen, nucleus accumbens and hippocampus) in people with ADHD compared with controls, effects most pronounced in childhood. Later ENIGMA work extended this to cortical thickness and surface area. Twin and family studies put heritability at roughly 70–80%, among the highest of any psychiatric condition and comparable to height; genome-wide association studies have identified specific common genetic variants associated with ADHD, and these findings replicate. The 2021 International Consensus Statement on ADHD, signed by over 80 senior researchers across 27 countries and summarising more than 200 evidence-based conclusions drawn from studies of hundreds of thousands of participants, states plainly that claims ADHD does not exist are “contradicted by a large body of research.” None of this means every person with the diagnosis has a scan that looks different — individual variability is large, exactly as Professor Rubia says — but the leap from “can’t be read off one scan” to “doesn’t exist in the material reality of the brain and body” is not a scientific conclusion; it is a rhetorical one, and it sits uneasily even with the researcher’s own published body of work over thirty years of imaging ADHD.

Is ADHD a ‘social construct’, and do we agree?

“This is really two claims wearing one label, and the documentary trades on the ambiguity between them. In one sense, yes: the threshold at which a pattern of inattention or impulsivity becomes a diagnosable “disorder” is set by expert consensus, reviewed periodically, and inevitably involves judgement about where normal human variation tips into clinically significant impairment. That is true of every diagnostic category in medicine — the blood pressure at which we call someone hypertensive, the BMI at which we call someone obese, the mood-symptom count for major depression — all of these are constructed thresholds on continuous human variation, agreed by clinicians and revised as evidence accumulates. Describing the threshold as constructed is banal, not damning.

“Where the documentary goes further, and where the evidence does not support it, is the claim that this makes the underlying difficulty, and the biological differences and heritability that predispose to it, not real — “a subjective imagination.” Genes, twin-study heritability and group-level brain differences are not something a committee invents; the diagnostic label organising them for clinical use is a human construction layered on top of something that pre-exists it. Conflating “the category has a constructed boundary” with “the phenomenon inside the boundary is fake” is a common but identifiable logical slip, and it is the same move critics have made, unsuccessfully, against most other psychiatric diagnoses over the decades. So: we agree the diagnostic threshold is a construct, in the same limited sense every diagnostic threshold in medicine is; we disagree that ADHD’s traits, distress, impairment and biology are therefore not real.

Is it safe to stop ADHD medication ‘cold turkey’, and what should someone who’s considering it do?

“No — not without medical involvement, and the programme’s own framing (“coming off the drugs for Mason is going to be really difficult because he’s coming off cold turkey”) already flags the risk it then treats as an incidental side detail. Stopping stimulant medication abruptly is associated with rebound symptoms — a resurgence of inattention, irritability and emotional reactivity that can be more pronounced than the original baseline for a period — as the brain readjusts after prolonged exposure. NICE’s evidence review on withdrawal (part of guideline NG87) found that stopping medication is consistently associated with a return or worsening of ADHD symptoms, particularly in children and young people, and recommends any decision to stop is made collaboratively with the prescriber, ideally as part of a planned, gradual taper with monitoring, and not undertaken unilaterally.

“Anyone who has watched the programme and is now considering stopping their own or their child’s medication should be advised, clearly and without alarm, to speak to their prescriber first rather than stop abruptly: to review, with that clinician, why the medication was started and what it is currently achieving; to plan any change as a supervised, gradual reduction rather than an overnight stop, so response can be monitored and rebound managed; and to know that deciding to pause or stop medication is a legitimate and normal part of ongoing ADHD care — NICE requires an annual review that explicitly includes discussing whether to continue — but it works far better, and more safely, as a planned conversation than as a response to a television programme.

On NICE and ‘drug holidays’ specifically

“It is true that NICE guidance discusses planned treatment breaks (“drug holidays”), and it is worth being precise about what that actually means, because the film’s use of “cold turkey” bears little resemblance to it. NICE’s own evidence review found only very limited, low-quality evidence for planned breaks (the main study examined weekend-only breaks in children), concluded any apparent benefit likely reflected the limitations of that evidence rather than a genuine advantage, and specifically cautioned that encouraging breaks risks worse overall adherence to treatment. Where breaks are used in practice, they are specialist-led, planned, reviewed, and historically mostly relevant to monitoring growth in children on long-term stimulant treatment — not a general recommendation to periodically stop, and certainly not a template for a full, unsupervised six-week discontinuation triggered by a TV experiment.

Was a video-call interview a standard diagnostic assessment?

“Remote (video) consultation is an accepted mode of delivery in NHS and GMC practice and is not, by itself, the issue — what matters is the content and thoroughness of the assessment, not the medium. NICE, the Royal College of Psychiatrists’ good-practice guidance (CR235) and the UK Adult ADHD Network’s quality standard converge on what a proper assessment requires: a full clinical and psychosocial history, a developmental history reaching back to childhood, ideally corroborated by a collateral informant who knew the person as a child (a parent, older sibling, or old school reports) and someone who knows them now, a semi-structured interview built around concrete real-life examples rather than yes/no ticks, validated rating scales interpreted in clinical context rather than scored in isolation, a mental state examination, and screening for the co-occurring conditions — anxiety, depression, autism, substance use — that affect the majority of adults with ADHD. This typically takes two hours or more of clinical time. An ADHD diagnosis should never rest on a questionnaire or a single self-report conversation alone; this is the RCPsych’s own stated position, including in its response to this documentary.

“The single assessment shown in the film cannot be judged reliably from the sequence, but the process it depicts — without visible collateral history-taking, developmental record review or comorbidity screening — is not, on its face, meeting that standard, and £1,200 for 45 minutes to an hour is a red flag for thoroughness regardless of the outcome. That is a genuine and serious issue, but it is an argument for scrutinising and improving assessment quality — exactly what the RCPsych, the ADHD Taskforce and CQC are all independently calling for — not an argument that the diagnostic category itself is invalid. A bad assessment for a real condition is still a bad assessment; it doesn’t retroactively make the condition fictional.  There was no discussion of how the functional impairment was discussed or handled?

What do we know about the validity of diagnoses from private clinics?

“Explosive, evidenced growth in demand has met chronically under-resourced NHS adult ADHD services — the Independent ADHD Taskforce found adults waiting up to eight years for assessment in some areas — and private clinics have filled that gap at scale; NHS commissioners themselves now spend heavily on independent providers to manage waiting lists. This creates a genuine two-tier problem the RCPsych, CQC and the Taskforce have all flagged: variable quality, weak regulatory oversight (the CQC has faced criticism for inconsistent inspection of neurodevelopmental services, with some providers going uninspected for long periods), and a real financial incentive for high-volume providers to shorten assessments. Concerns about profit-driven, corner-cutting private providers are legitimate and worth investigating journalistically.

“What that evidence does not show is that private-sector diagnosis is systematically wrong in one direction. Poor-quality, rushed assessment can drive both over- and under-diagnosis — a superficial tick-box process can wrongly diagnose someone who doesn’t meet threshold, and can equally wrongly clear someone who does, particularly women and adults whose presentation doesn’t match the stereotyped hyperactive-boy picture and who are already known to be under-recognised. The Taskforce’s own conclusion, drawing on national and international prevalence data, is that England has been under-diagnosing relative to comparable countries and to the 3–5% prevalence estimate, not over-diagnosing overall. The right response to variable private-sector quality is regulation, published quality standards and NHS capacity — all things the Taskforce report recommends — not a conclusion that the underlying diagnosis is a myth.

Other comments on the documentary’s claims and conclusions

“Stepping back, the film’s central thesis — that ADHD is not a genuine neurodevelopmental condition, has no biological basis, and is best understood as a social construct invented to medicate away difficult or inconvenient behaviour — is contradicted by the WHO’s ICD-11, the DSM-5-TR, NICE guideline NG87, the Royal College of Psychiatrists, and the 2021 International Consensus Statement signed by more than 80 leading researchers across 27 countries. Several editorial choices in the programme are worth flagging explicitly:

•     Several contributors are established, long-standing critics of psychiatric diagnosis generally (not ADHD specifically), and at least one cited source predates the last decade of imaging and genetic evidence by ten years or more — presented without that context alongside an exchange with a mainstream imaging researcher whose own extensive published work over three decades documents group-level structural and functional brain differences in ADHD.

•     False balance. Fringe positions (“certainly not a medical condition,” ADHD as pure invention) are given equal narrative weight to a position backed by the international research consensus, twin studies, GWAS data and every major clinical guideline body.

•     A single child’s medication withdrawal, filmed for entertainment, used as the emotional and narrative proof of a scientific conclusion — addressed in full above.

•     The final report of the Independent ADHD Taskforce (November 2025) reaches the opposite conclusion to the documentary: it frames the current situation as a story of historic under-investment and access failure — up to eight-year waits, an estimated £17bn annual cost to the economy and public services from unmet need — calling for ADHD to be “recognised and treated as a common condition,” with better integrated, needs-led pathways, not for the diagnosis to be withdrawn or medication use rolled back.

Refuting analogies used in the film- “We’ve replaced corporal punishment with giving them a pill”

“This analogy only works if you ignore both the evidence base and the intent behind each practice. Corporal punishment was never supported by controlled evidence of benefit; decades of research instead show it causes psychological harm, and it has been progressively abandoned and legally restricted precisely because the evidence turned decisively against it. ADHD medication is the opposite case: it rests on well over a hundred randomised, placebo-controlled trials and tens of thousands of participants showing measurable benefit, its mechanism of action is pharmacologically characterised, its risks are monitored through structured review, and — critically — it is prescribed to reduce a person’s own reported distress and impairment (accidents, school failure, social difficulty, suicide risk), not merely to make a child easier for adults to manage. The claim conflates “an intervention that changes a child’s behaviour” with “an intervention imposed for adult convenience with no evidence of benefit to the child” — but those are not the same thing, and effective treatments in general change behaviour all the time (an anticonvulsant that stops seizures also changes what a child can safely do) without that being evidence of coercion. It is also, unlike corporal punishment, entirely reversible, individually titrated, and undertaken with informed consent from the patient and/or family.

“This comparison inverts the very reasoning that makes conversion therapy so widely condemned. Conversion ‘therapy’ targeted something that was never a disorder — sexual orientation causes no inherent impairment — and was denounced specifically because it had no evidence of efficacy and consistent evidence of serious harm (increased depression, anxiety and suicidality), a judgement the Royal College of Psychiatrists itself, along with every other major UK medical and psychological body, has formally endorsed via the Memorandum of Understanding on Conversion Therapy. ADHD treatment targets a condition defined by measurable functional impairment, is supported by an extensive positive efficacy and safety evidence base rather than an absence of one, and — unlike conversion therapy, which by design tried to permanently change an innate, non-pathological characteristic — is fully reversible and does not attempt to alter who someone is, only to reduce symptoms that the person themselves typically wants relief from. Comparing a well-evidenced, consent-based, reviewable medical treatment to a discredited practice that had no evidence of benefit and demonstrated harm is a powerful rhetorical device, but it does not survive contact with what actually distinguishes the two: evidence of benefit versus evidence of harm, and treating a symptom versus attempting to erase an identity.”

Prof Philip Asherson, Emeritus Professor of Neurodevelopmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, said:

“I note they focused on children as adults can choose for themselves whether to take medication or not. This is an important distinction. With children it’s particularly important to balance out benefits from adverse effects, paying careful attention to these effects and taking the wishes of the child into account. It was important to find out that in the film the child preferred not to use medication and was happier without. In his case he appeared to be more social and peers liked this, so there was a strong case to stop medication despite the negative impact on his education. However he would need a lot of additional support and the long term impact on his education and self/esteem may be very damaging. A good alterative is to consider trying lower doses, or using medication for part of the day. 

“Some children with ADHD are the clowns that people laugh at and developing social connections can be a struggle. Many untreated children with ADHD develop a negative self-critical mindset, low confidence and poor self-esteem. Risks for developing substance use, anxiety, depression and personality disorder are increased.

“The film showed a positive and supportive school and parenting. These are all very beneficial protective factors. It is true that some people with ADHD thrive and they are often well supported /accommodated by school and family, but this is not always the case. As indicated for children, learning how to best to manage ADHD and tailor the environment can make a huge difference. Nearly all people with ADHD can do some activities things they find interesting/motivating well and this should be nurtured. The decision to use medication should as indicated only follow on from reasonable non-pharmacological support paying attention to both school and out of school situations. Medication is used when severe problems remain that are detrimental to the child now and into the future. Overall it’s a more difficult decision with children as they have little choice, especially in 10-14 age group. This demonstrates the need for effective support services both in education and health services, yet child social, educational and mental services are all severely stretched. The boy in the film might well benefit by going back on medication if his social and educational development suffer. This would need to be closely monitored. A short period off medication with considerable support from family and school is not sufficient to evaluate the longer term impact.

“Certainly they portrayed a boy with ADHD. Not a myth or social construct.

In response to some specific claims/ points in the documentary made in the documentary:

What can the ‘experiment’ with Mason actually tell us? 

“For this individual child, he appeared to be happier and more social off medication in the short term, but that medication had a big positive impact on his formal education. He was fortunate to have strong support from school and home. He had learnt a lot about his own ADHD through the experience of taking medication. It was mentioned that he might go back on medication later if needed. 

The programme suggests multiple factors as interventions for Mason in addition to coming off medication (e.g. no sugary sweets, no processed food, time in nature, no screen use, supplements). What is the evidence base for the impact of this on ADHD?

“The evidence base for these is very limited and poor. There is some evidence for fish oils, avoiding certain food additives, and one RCT using nutritional supplements so very limited data. Good diet and exercise, time in nature and limiting screen time is good for everyone, and could reduce the severity of ADHD. I’d encourage this but these are rarely sufficient solutions for children with ADHD.

What is the evidence base on efficacy and safety of ADHD medications? 

“There is good evidence on both from numerous RCTs. These indicate short term effects. Prescribers should be knowledgeable and mindful of both benefits and adverse effects. Titration to find optimal dose with benefits while limiting adverse effects is essential. Takes time, skill and experience. 

What about side effects such a less energy or being ‘less fun’?

“Yes – these can be a problem. Reducing energy might be desired depending on severity. Some children and adults like /enjoy their active mindset and high energy levels – but can be considered as a class clown by peer group. 

“Others are very distressed. Some will be far happier on medication as calmer, more in control, and might make more friends-be more social rather than less. 

“It is possible to tailor medication to have periods both on and off medication. I’d always take the child’s view into account. Every child is different and paying attention to all potential adverse effects is critical. 

Is it safe to come off ADHD medication ‘cold-turkey’?

“Yes – in most cases not a problem. Children often not treated during holiday periods or weekends. If on medication and thinking about this I would always discuss first with an experienced professional. 

They speak about brain imaging being unable to differentiate a brain with and without ADHD and later conclude that ADHD is ‘not a disorder of the brain’ with no biological marker and one person saying ‘it doesn’t exist in the material reality of the brain and body’- what are your comments on this?

“That would mean that all psychiatry and autism do not reflect real conditions, which is clearly not true. As mentioned there are group differences that indicate the type of processes involved, but there is so much variability in brain structure/function that brain scans are no where near sensitive enough or reliable enough to detect individual differences.

“There is a chapter in NICE on validating criteria for these conditions and many excellent summary papers we can cite. Importantly ADHD can be reliable measured even though this was questioned in the program, and many consistent associations are described in a very extensive literature. 

They also conclude that ADHD is a ‘social construct’ – what does that mean and do you agree?

“ADHD can be reliably measured. Features of ADHD are distributed throughout the population like height, blood pressure, weight etc. ADHD (the clinical disorder) is the extreme and impairing tail of a continuously distributed trait(s).  This does mean that society had decided on a level of impairment that people need help with to prevent both current and future harm. Individual views on how impaired or distressed they feel should also be taken into account. 

“For blood pressure we treat even when asymptomatic with no impairment, to reduce future risk. With ADHD we only treat if impairment is present and sufficiently severe. How we set these thresholds of impairment are important  for individuals and society to consider. Few, if any, would argue that someone with severe ADHD does not need social, educational or medical interventions, but where do we draw the line. Society and medicine has to decide.  By its nature a line must be drawn like obesity and other continuous traits treated at the extremes of normal variation. 

The clinical assessment was a video call interview? Is that the standard way people are diagnosed?

“The video call can limit the quality of information but not usually a problem with adults. I would not use video for children. Face to face is better. But I would question the quality of the assessment not the use of the video. If, as indicated, there were no obvious areas of significant impairment needing an intervention the diagnosis should never have been made. The doctor had no need of medication. Were other explanations explored? It seems he had some traits of ADHD but did not meet the impairment criteria which are essential to the clinical diagnosis. The process should be to establish problems / impairments  that someone wants help with, to decide if sufficient for a medical, social and/or educational intervention. Then decide if ADHD or another condition, or any identifiable situations exacerbating the problems. 

They question the role of private clinics – what do we know about the validity of diagnoses from private clinics?

“We do not! There is a lack data on this. No published quality control. We are concerned about poor practice and lack of knowledge/experience, but largely based on opinion rather than any systematic evaluation. It’s a problem. So we need data to evaluate this. What are outcomes? How many do well? How many have to seek further help from the NHS. How often is the diagnosis a misdiagnosis of another condition, or no condition. I agree with potential for money making schemes rather than good medical practice. Many assessors in these clinics are not psychiatrists.” 

Professor Maddie Groom and Dr Elizabeth Liddle on behalf of the members of the Institute of Mental Health’s Centre for ADHD and Neurodevelopmental Disorders Across the Lifespan (CANDAL), said:

 “The Great ADHD myth asks “whether ADHD is a genuine neurological disorder, or a social construct”.

“The question is profoundly misleading. 

“ADHD is indeed a “social construct” –  defined by behaviours that are contextually “inappropriate”.

“It also has serious long-term academic, vocational and healthcare impacts that are greatly ameliorated by timely recognition and effective support – which may or may not include medication.  This would make it a “genuine” condition, whether or not it had neural and genetic correlates – which it does.

“The construct is certainly problematic –  essentially, a set of externally observable behaviours that rarely reference any inferred underlying inner experience, and are biased by the way the trait typically presents in boys and by cultural and ethnic bias in how behaviour is interpreted. It is a partial, biased, and stigmatising conceptualisation of the underlying trait, missing many of those who need support, and  capturing none of the strengths the trait may confer in other contexts.

“None of that makes ADHD a myth. Insinuating so won’t shorten waiting lists.

“Instead, ADHD services need fundamental reform, to provide timely functional support to meet contextual challenges and find compensatory strengths, and access to both medication and non-pharmacological therapies according to need.”

Dr Rachel Moseley, Principal Academic in Psychology, Bournemouth University, said:

“This pseudo-scientific programme ignores a wealth of rigorous evidence inconvenient for its central premises: that ADHD is a social construct, overdiagnosed and over-medicated. First, the programme leans into neuroscience  – oversimplified and misinterpreted – to support the claim that ADHD is not a neurodevelopmental disorder but a ‘social construct with no basis in the brain or body’. They base this on the argument that there isn’t a clear or single neurological difference characterising ADHD, and you can’t diagnose it from a brain scan. This is true because brains, and ADHD, are much more complicated than this. Science has shown us that the features that comprise the diagnostic construct of ADHD (e.g. inattentiveness, hyperactivity-impulsivity) exist on a dimensional continuum across the general population, and these features have a very real, pretty well-established basis in the brain (see, for instance, Prium et al., 2019; Sonuga-Barke et al., 2023) – but categorically diagnosing people with ADHD requires clinicians to make a judgement call as to when a *higher level of features* gives rise to clinical impairments across everyday life (e.g. in education, employment, relationships). Because of this, and because of the fact that ADHD people all differ slightly in their constellation of features (e.g. inattentive features, sensory sensitivities, hyperactivity), we will *never* find a single brain profile associated with ADHD. This in no way whatsoever equates to ADHD being socially constructed or not a neurodevelopmental condition, as the presenter concludes. ADHD actually has a greater genetic i.e. biological basis, than most mental illnesses (as explained in a recent review Sonuga-Barke et al., 2023), and this speaks against a causal role for environmental factors like screen time or ultra-processed food.

“The ‘experiment’ with Mason was not an experiment. Nor was it a case study. It was an uncontrolled exercise for entertainment’s sake, which teaches us nothing: the child and the family were very aware of the film crew and the narrative of the documentary, and many factors changing during the very short and artificial “test” period means that any changes in the child’s behaviour cannot be attributed to stopping medication (they might, for instance, be related to the stress and/or excitement of being followed by TV cameras). There is also the factor that the child was growing into puberty; an experiment would, in addition to being properly powered with an adequate sample, include appropriately matched comparison groups such as same-aged individuals who continued taking their medication for the same study period, while holding other factors constant between the two groups. We would then be able to understand if changes might be attributable to medication. To suggest that ADHD medication is unhelpful and detrimental, on the basis of an uncontrolled and entirely unscientific exercise involving a single child, is contradicted by robust evidence that ADHD medication is associated with increased life expectancy (Li et al., 2024), and with reduced risk of suicide among other negative outcomes (Zhang et al., 2025). A recent meta-analysis of randomised controlled trials found that ADHD medication was more efficacious than placebo conditions and a range of comparisons (including CBT, mindfulness) in controlling ADHD features over 12 weeks. 

“Assessments for ADHD, and then for ADHD medication, are detailed and lengthy. ADHD is *never* diagnosed on the basis of a single screening test as portrayed, nor on chance instances of normal childhood behaviours like fidgeting, as implied. ADHD is diagnosed on the basis of well-tested diagnostic criteria which require evidence of prolonged difficulties evidenced across multiple contexts and over time (symptoms’ should have been present for at least six months and started before the age of 12), and diagnosis ideally involves corroboration by multiple informants.  Moreover, to imply that clinicians are over-zealous in dispensing diagnoses and medication – “drugging so many young people”, in one speaker’s words, or “pouring substances” into children as stated by the presenter – is a gross distortion of reality.  Proportionally few children and adults are receiving medication for ADHD (French et al., 2025), and those who are have faced long, distressing waits to receive medication (on top of years-long waits for initial ADHD assessment), as shown in a recent Healthwatch report and a scientific review. ADHD medication is not easily dispensed, but again subject to a healthcare professional’s assessment of the patient’s best interests.

“More people are being diagnosed today than were diagnosed ten or twenty years ago – yes. Does this mean that ADHD is overdiagnosed – i.e. that diagnoses are illegitimate or in some way unreal? No. Apart from the fact that a large body of work shows that ADHD is still markedly underdiagnosed in the UK (with almost 94% of ADHD people over age 65 undiagnosed), there are many reasons why diagnoses are increasing – and why this is a GOOD thing.  Chief among the reasons for rising diagnoses is that a) we’re much better at identifying ADHD, especially in people traditionally overlooked, like girls, women and ethnic minorities; b) we’re now aware that even less obvious or apparently “mild” ADHD-related differences – in people who, indeed, might have been overlooked ten or twenty years ago – have enormous impacts on people’s lives and opportunities, which is why our diagnostic thresholds have widened to include these individuals. We know, for instance, that undiagnosed and unsupported ADHD is associated with some devastating outcomes, including educational exclusion, unemployment, mental illness and suicide (French et al., 2023). By starting from the premise that ADHD is “overdiagnosed” and framing increasing rates of diagnosis in a dubious, negative light, the programme ignores robust scientific evidence that even people with “mild” features of ADHD are subject to these kinds of detriments if not diagnosed and supported – as such, many academics consider increased recognition of neurodivergent people as a very positive thing, as it allows us opportunities to intervene before people reach crisis point (Moseley-Braund et al., 2026). It also ignores the immensely positive value that a diagnosis can have in helping ADHD people understand themselves, be more self-compassionate, improve their relationships, self-care and self-regulation (as in our recent work, and in this report by Healthwatch). 

“Calling ADHD a social construct has extremely severe ramifications in increasing stigma against those who hold ADHD diagnoses or are waiting for assessment. We know that programmes like this increase stigma, and we know that stigma is associated with mental illness in neurodivergent people (Masuch et al., 2025; Moseley et al., 2025). We also know that many children and adults wait for ADHD assessment while struggling with their mental health and daily lives, and few receive any support while waiting, which makes them very vulnerable (see Healthwatch report, 2025). Our own work also tells us that invalidating the experiences, needs and difficulties of neurodivergent people  – as the programme does  – causes severe psychological distress.

“Channel 4 prides itself on being “progressive”, on “making informed choices”, seeking “underrepresented perspectives, consulting those with lived experience and groups representing communities’ voices”. It is as such extremely disappointing to see them air such an uninformed, pseudo-scientific, inflammatory and irresponsible programme, particularly after they were informed that the programme would increase harmful ADHD stigma in an open letter by a coalition of academics, professionals and people with lived experience of ADHD. Far from being “taking on conventional thinking on ADHD”, the programme jumps on the bandwagon of a dangerous trend, especially prevalent in the past year, which questions the validity and legitimacy of needs associated with ADHD and autism diagnoses, those who hold them and those who seek them. 

Declared interests

Prof Anita Thapar: I am a clinician scientist.

I have served as Chair of NHS England Independent ADHD Taskforce and a member of the DfE Neurodivergence Task and Finish Group (unpaid).

I also served as co-chair on the Welsh Government Neurodivergence Ministerial Advisory Group (unpaid)”

Dr Jessica Eccles: Qualified 2006, Starting training in clinical academic Psychiatry in 2008, Became Member of Royal College of Psychiatrists in 2011, a specialist consultant in 2018 and Fellow in 2023. Consultant Psychiatrist in a Neurodevelopmental Service since 2020.  Working in the field of neurodevelopment since 2009.  Numerous research funding from Charities and Research Councils, including ADHD UK. No Honoria or support from drug companies.  Member of Clinical Reference Group of the ADHD Taskforce.  Interweaving Workstream Lead for the Neurodevelopmental Credential, Faculty RCPSYCH Adult ADHD Programme, RCPSYCH National Autism Training Programme, Chair RCPSYCH Neurodevelopmental Psychiatry Group (Since 2024).  Limited private consultant neurodevelopmental practice.  Strong track history of public engagement, hosts YouTube Channel @BendyBrainDrJessica Eccles. Dr Eccles discovered she was neurodivergent herself and has a number of physical and mental health related challenges.  She has lost members of her family to ADHD related harm.

Prof Philip Asherson: In the last 5 years, Asherson received payments for consultancy and/or educational talks from Neuraxpharm, Johnson and Johnson, Takeda, Jannsen, Flynn Pharma, Medice, Neuraxpharm, Bedrock Health, WE Pharma Limited, InfectoPharm, AGB Pharma; and royalties from PATOSS, Cambridge University Press and Oxford University Press. He is paid for delivering training on management of ADHD by UKAAN. He is Honorary President for the UK Adult ADHD Network (UKAAN).

Dr Elizabeth Liddle: I have a revenue-sharing agreement with the University of Nottingham in connection with a computer game we are developing as a school-based resource to help children with ADHD learn better control over where they are looking.

Dr Rachel Moseley: No conflicts of interest

For all other experts, no reply to our request for DOIs was received.